JP2022501336A5 - - Google Patents

Info

Publication number
JP2022501336A5
JP2022501336A5 JP2021514344A JP2021514344A JP2022501336A5 JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5
Authority
JP
Japan
Prior art keywords
polypeptide
optionally
phytosterols
seq
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501336A (ja
JP7556848B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051072 external-priority patent/WO2020056304A1/en
Publication of JP2022501336A publication Critical patent/JP2022501336A/ja
Publication of JP2022501336A5 publication Critical patent/JP2022501336A5/ja
Application granted granted Critical
Publication of JP7556848B2 publication Critical patent/JP7556848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514344A 2018-09-14 2019-09-13 mRNA治療薬を使用したがんを治療するための方法及び組成物 Active JP7556848B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862731335P 2018-09-14 2018-09-14
US62/731,335 2018-09-14
US201862770024P 2018-11-20 2018-11-20
US62/770,024 2018-11-20
US201962881322P 2019-07-31 2019-07-31
US62/881,322 2019-07-31
PCT/US2019/051072 WO2020056304A1 (en) 2018-09-14 2019-09-13 Methods and compositions for treating cancer using mrna therapeutics

Publications (3)

Publication Number Publication Date
JP2022501336A JP2022501336A (ja) 2022-01-06
JP2022501336A5 true JP2022501336A5 (https=) 2022-09-20
JP7556848B2 JP7556848B2 (ja) 2024-09-26

Family

ID=68104746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514344A Active JP7556848B2 (ja) 2018-09-14 2019-09-13 mRNA治療薬を使用したがんを治療するための方法及び組成物

Country Status (7)

Country Link
US (1) US20230081530A1 (https=)
EP (1) EP3849589A1 (https=)
JP (1) JP7556848B2 (https=)
CN (1) CN113015540A (https=)
AU (1) AU2019338535A1 (https=)
CA (1) CA3112781A1 (https=)
WO (1) WO2020056304A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US20220280639A1 (en) * 2019-07-31 2022-09-08 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
WO2021231854A1 (en) * 2020-05-14 2021-11-18 Modernatx, Inc. Lnp compositions comprising an mrna therapeutic and an effector molecule
US12188060B2 (en) 2020-05-15 2025-01-07 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
EP4175676A4 (en) * 2020-07-06 2024-08-28 Vivtex Corporation MUCO-PENETRATING FORMULATIONS
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2022120560A1 (zh) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
KR20240017793A (ko) * 2021-04-17 2024-02-08 인텔리아 테라퓨틱스, 인크. 지질 나노입자 조성물
WO2022228492A1 (zh) * 2021-04-29 2022-11-03 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
US20220364078A1 (en) 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
US12251471B2 (en) * 2021-07-26 2025-03-18 Oregon State University Inhalable therapeutics
CN114457054A (zh) * 2022-02-24 2022-05-10 中国科学技术大学 一种cGAS mRNA的制备及作为免疫激活剂的应用
CA3246723A1 (en) * 2022-03-30 2023-10-05 The Johns Hopkins University Lipid nanoparticle compositions for the delivery of plasma DNA to the liver and their preparation methods
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
WO2023246840A1 (en) * 2022-06-22 2023-12-28 Wuhan Houxian Biopharmaceutical Co. Ltd. Combination of il-12 and ox40l for cancer immunotherapy
US20260027162A1 (en) * 2022-07-15 2026-01-29 President And Fellows Of Harvard College Mucispirillum compositions and cancer treatment methods thereof
US20250387486A1 (en) * 2022-08-09 2025-12-25 Stemirna Therapeutics Co., Ltd. Lipid composition
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
EP4649087A2 (en) 2023-01-11 2025-11-19 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
EP4470559A1 (en) * 2023-06-02 2024-12-04 Imgen-T-Srl Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy
WO2025098508A1 (zh) * 2023-11-10 2025-05-15 贝达药业股份有限公司 标记性多肽、治疗剂及其应用
CN119662655A (zh) * 2023-12-04 2025-03-21 武汉厚先生物医药有限公司 Rna分子及其组合物在肿瘤免疫治疗中的应用
WO2026078565A1 (en) 2024-10-10 2026-04-16 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447370B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
NZ599338A (en) * 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
CA2715078C (en) 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
EP3197911A4 (en) * 2014-09-22 2018-06-20 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
PL3394093T3 (pl) * 2015-12-23 2022-05-16 Modernatx, Inc. Metody stosowania polinukleotydów kodujących ligand ox40
JP7194594B2 (ja) * 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用
JP2019519516A (ja) * 2016-05-18 2019-07-11 モデルナティーエックス, インコーポレイテッド がんの治療のためのmRNA併用療法
SI3458083T1 (sl) * 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
EP3523323A4 (en) * 2016-10-07 2020-06-17 Board of Regents, The University of Texas System T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
JP7285220B2 (ja) * 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Similar Documents

Publication Publication Date Title
JP2022501336A5 (https=)
Liu et al. Advances in immunotherapy for triple-negative breast cancer
US8367628B2 (en) Amphoteric liposome formulation
Xu et al. Endogenous sialic acid-engineered micelles: a multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis
JP2020520640A5 (https=)
JP2023552195A5 (https=)
CN104903450A (zh) 寡核苷酸癌症疗法的给药和施用
EP3603748A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
JP5623016B2 (ja) 癌治療法およびそれに用いる医薬組成物
JP2020111589A (ja) リポソーム製剤
Fan et al. Lipid-based nanoparticles for cancer immunotherapy
CN104884637A (zh) 利用生物标志物通过bcl2表达的调节治疗癌症的方法
CN108310378A (zh) 一类新型免疫联体抗肿瘤创新药物的制备及其应用
JP2022525223A (ja) sEphB4-HSA融合タンパク質を用いたがんの治療
TW202114647A (zh) 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑
KR20240158980A (ko) 유기 화합물
WO2009051712A1 (en) Dnai amphoteric liposome formulation
CN108883068A (zh) 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法
WO2024137776A1 (en) Combination therapy for lung cancer
AU2023226175A1 (en) Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof
WO2007065017A2 (en) Oligonucleotide cationic liposomal delivery system
WO2020160409A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
WO2022097634A1 (ja) 血管新生依存性疾患治療に使用される医薬用組成物
CN116621966B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
WO2023121960A2 (en) Compositions and methods for delivery and production of antibodies using an rna-containing nanoparticle platform